How do systemic lupus erythematosus patients with very-long disease duration present? Analysis of a monocentric cohort.


Journal

Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265

Informations de publication

Date de publication:
Mar 2021
Historique:
pubmed: 9 1 2021
medline: 16 10 2021
entrez: 8 1 2021
Statut: ppublish

Résumé

to describe the disease path and the very long-term outcome in a monocentric cohort of patients with Systemic Lupus Erythematosus (SLE). SLE patients with a disease duration of at least 15 years from diagnosis were enrolled. The number of hospitalizations, the disease flares occurred over the disease course and the organ damage accumulation were evaluated at 1, 2, 3, 4, 5, 10 years from diagnosis and at last observation in 2019 as well. Disease state, ongoing therapies and quality of life measures were also assessed at last visit. 126 Caucasian SLE patients were included in the analysis (95% female, median age 47.5 IQR 41-53, median disease duration 21 IQR19-26). At last visit, the majority of the patients (78.6%) was on LLDAS (remission included), 53.4% were on GC treatment and 35.7% on immunosuppressant. Furthermore, 53.2% had at least one organ damage. The majority of patients (66.7%) presented a relapsing-remitting course, for a total of 158 flares during the disease course (incidence rate: 0.79/patient-year); moreover, 84.9% of the cohort experienced at least one hospital admission, amounting to a total of 328 hospitalizations (incidence rate: 0.85/patient-year). The main reason for admission was disease activity, while the percentage of hospitalizations due to other causes has been growing over the 10 years of follow-up. after a very long period of disease, most of the patients with SLE are in remission and are not taking GC therapy; however, the risk of incurring in disease flare remains a real problem.

Identifiants

pubmed: 33413007
doi: 10.1177/0961203320984230
doi:

Substances chimiques

Glucocorticoids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

439-447

Auteurs

Viola Signorini (V)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Chiara Tani (C)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Elena Elefante (E)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Linda Carli (L)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Chiara Stagnaro (C)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Dina Zucchi (D)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Alice Parma (A)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Roberta Vagelli (R)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Francesco Ferro (F)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Marta Mosca (M)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH